SAN DIEGO, CA--(Marketwire - October 19, 2009) - ChemDiv, Inc. (ChemDiv) of San Diego has
proudly announced that its wholly owned subsidiary Chemical Diversity
Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom
Ltd. ( Viriom) of Moscow, Russia as a service partner in developing
innovative HIV compounds. The program includes pre-clinical and clinical
studies, which are expected to begin in 2010.
Viriom has recently signed the license agreement with Roche. Under the
terms of this agreement Roche granted Viriom development and
commercialization rights for potential novel HIV/AIDS medicine in Russia,
Ukraine, Belarus and Kazakhstan. Subject to performance of the program
Viriom will also receive license fees, development milestones and royalties
on worldwide sales.
Vadim Bichko, Vice President Virology at ChemDiv, Inc., said: "We are
excited about this new collaboration with Viriom and Roche. These novel HIV
inhibitors have shown excellent antiviral properties in vitro, good
bioavailability, PK and safety profiles, as well as a high genetic barrier
to resistance. Based on pre-clinical studies to date, these molecules have
the potential to become best in class HIV drugs."
VIRIOM Ltd. is an innovative company that was established in 2009 to
develop targeted medicines for HIV/AIDS. Basis is the Center of High
Technologies ChemRar to which VIRIOM is affiliated. VIRIOM is planning to
conduct research and clinical trials in Russia using the experience and
knowledge of Russian scientists. Chemical Diversity Research Institute,
Prudentas Ltd. and Drug Technologies Ltd.of ChemRar Hi Tech Center
(ChemRar) as well as Moscow City Center for prevention and treatment of
HIV/AIDS were selected as partners in this program.
About ChemDiv, Inc.
ChemDiv collaborates with pharmaceutical and biotech partners by enabling
them to accelerate their R&D programs to higher value clinical inflection
points. ChemDiv provides integrated drug discovery and early clinical
development, extracting value from potential therapeutic candidates via
rapid, streamlined outcomes and effective use of capital.
ChemDiv is the only vertically and horizontally integrated discovery and
development CRO headquartered in San Diego, CA, with: unique access to the
Eastern European emerging pharma market; rational drug design and
medicinal chemistry in a broad range of therapeutic areas of target
classes; world's largest small molecule inventory; working with 20 top
pharma and 100 top biotechs in all major markets.
With its successful 20 year business record in life sciences and over 500
research associates equivalent employed globally, ChemDiv has successfully
prosecuted fully integrated programs from target to Proof of Concept (POC)
and market registration.
About Chemical Diversity Research Institute.
CDRI is a contract research organization focused on pre-clinical and
clinical R&D. CDRI sees its mission in enabling discovery and development
of innovative therapies for unmet needs utilizing the highest expertise
and innovation potential of Russian scientists with integrated external R&D
solutions of Discovery outSource™ platforms. Discovery outSource™
platform solutions cover the complete range of disciplines from
identification of a biological target (protein expression, assay
development etc.); to clinical drug candidates (ADME/DMPK, toxicity and
safety studies, in vivo animal models, drug formulation etc.); to drug
development candidate (Phase I to Phase IV).
About ChemRar Hi Tech Center
ChemRar High-Tech Center is a unique pharma and biotechnology conglomerate
built in Moscow, Russian Federation by highly innovative life science R&D
organizations, discovering, developing and commercializing novel drugs for
partners in Russia and worldwide. It sees its mission in bringing novel
therapies for unmet needs in treating CNS, oncology, cardiovascular,
metabolic and infection disease through using novel post genomic technology